Currently, the only precision medicine options for RAF-mutated lung cancer are dabrafenib (combined with trametinib) [18] and encorafenib (combined with binimetinib) [19], both of which target the BRAF p.V600 mutation in combination with MEK inhibitors. Here, MAP2K7 is linked to lung cancer.